v3.25.2
SEGMENT REPORTING (Tables)
 6 Months Ended
Jun. 30, 2025
Segment Reporting [Abstract]  
Schedule of Operating Financial Results of Therapeutics Segment
The following table provides the operating financial results of the therapeutics segment:
 Three Months Ended June 30,Six Months Ended June 30,
 2025202420252024
Revenues:
Product sales, net$102,660 $40,813 $180,995 $65,533 
License fees and collaboration revenue— — — 2,894 
Total revenues102,660 40,813 180,995 68,427 
Operating expenses:
Cost of sales6,237 3,004 11,448 4,658 
Research and development15,594 12,319 30,003 24,385 
Selling and marketing65,857 32,251 126,143 60,138 
General and administrative37,156 26,541 61,865 50,232 
Total operating expenses124,844 74,115 229,459 139,413 
Loss from operations(22,184)(33,302)(48,464)(70,986)
Other reconciling items(1)
1,844 12 3,004 1,965 
Net loss$(20,340)$(33,290)$(45,460)$(69,021)
Other segment disclosures:
Interest income$4,229 $4,130 $7,683 $7,247 
Interest expense$(2,240)$(2,109)$(4,453)$(3,092)
Depreciation and amortization expense$453 $239 $913 $509 
(1) Other reconciling items primarily includes interest income and interest expense. In the prior year periods, other reconciling items also included loss on debt extinguishment.